Dacomitinib Patent Expiration

Dacomitinib is used for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. It was first introduced by Pfizer Inc in its drug Vizimpro on Sep 27, 2018.


Dacomitinib Patents

Given below is the list of patents protecting Dacomitinib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Vizimpro US10596162 Method for treating gefitinib resistant cancer Feb 02, 2026 Pfizer
Vizimpro US10603314 Method for treating gefitinib resistant cancer Feb 02, 2026 Pfizer
Vizimpro US7772243 4-phenylamino-quinazolin-6-yl-amides Aug 26, 2028 Pfizer
Vizimpro US8623883 4-phenylamino-quinazolin-6-yl-amides May 05, 2025 Pfizer


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dacomitinib's patents.

Given below is the list recent legal activities going on the following patents of Dacomitinib.

Event Date Patent/Publication
Patent litigations
transaction for FDA Determination of Regulatory Review Period 28 Dec, 2023 US7772243
transaction for FDA Determination of Regulatory Review Period 08 Dec, 2023 US7772243
Payment of Maintenance Fee, 4th Year, Large Entity 13 Sep, 2023 US10603314
Payment of Maintenance Fee, 4th Year, Large Entity 06 Sep, 2023 US10596162
Payment of Maintenance Fee, 12th Year, Large Entity 13 Jan, 2022 US7772243
Payment of Maintenance Fee, 8th Year, Large Entity 10 Jun, 2021 US8623883
Second letter to regulating agency to determine regulatory review period 27 May, 2021 US7772243
Sequence Moved to Public Database 31 Mar, 2020 US10603314
Patent Issue Date Used in PTA Calculation 31 Mar, 2020 US10603314
Recordation of Patent Grant Mailed 31 Mar, 2020 US10603314



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳